TheraRadar
← Back
Data updated: Jun 28, 2026

HENGRUI PHARMA

Generics
OncologyRespiratoryDermatology Execution: Fair

HENGRUI PHARMA is a generic drug manufacturer focused on Oncology, Respiratory, Dermatology.

2011
Since
17
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

HENGRUI PHARMA at a Glance

  • Fast trial execution (12 months median completion)

HENGRUI PHARMA's Key Drugs

HENGRUI PHARMA's core commercial portfolio centers on CISATRACURIUM BESYLATE PRESERVATIVE FREE, spanning Oncology and Respiratory — its most strategically important drugs approved in the last 15 years.

CISATRACURIUM BESYLATE PRESERVATIVE FREE
Other

Tracheal intubation

cholinergic receptor Approved 2012

HENGRUI PHARMA's Recent FDA Approvals

HENGRUI PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections

HENGRUI PHARMA's Therapeutic Areas

HENGRUI PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 43%
4 drugs Phase 3: 2 Phase 2: 4 Phase 1: 25
Respiratory 24%
1 drugs Phase 3: 2 Phase 2: 6 Phase 1: 10
Dermatology 16%
1 drugs Phase 3: 2 Phase 2: 4 Phase 1: 2
Immunology 9%
0 drugs Phase 2: 5 Phase 1: 4
Infectious Disease 8%
2 drugs

HENGRUI PHARMA's Top Competitors

HENGRUI PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, GSK, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Dermatology
GSK big-pharma
Respiratory, Infectious Disease, Oncology, Immunology
Novartis big-pharma
Oncology, Respiratory, Immunology
Merck big-pharma
Oncology, Infectious Disease, Respiratory
PHARMACIA AND UPJOHN big-pharma
Dermatology, Infectious Disease, Respiratory, Immunology

HENGRUI PHARMA Pipeline Snapshot

HENGRUI PHARMA has 66 active clinical programs from ClinicalTrials.gov — 6 Phase 3, 19 Phase 2 and 41 Phase 1.

6
Phase 3
19
Phase 2
41
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CISATRACURIUM BESYLATE PRESERVATIVE FREE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 40/81 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges